103 related articles for article (PubMed ID: 21863614)
1. Pharmacogenetics of oral antidiabetic treatment.
Schroner Z; Javorsky M; Kozarova M; Tkac I
Bratisl Lek Listy; 2011; 112(8):441-6. PubMed ID: 21863614
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacogenetics of oral antidiabetic treatment].
Tkáč I
Vnitr Lek; 2016 Mar; 62(3):186-8. PubMed ID: 27180666
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of oral antidiabetic therapy.
Ordelheide AM; Hrabě de Angelis M; Häring HU; Staiger H
Pharmacogenomics; 2018 Apr; 19(6):577-587. PubMed ID: 29580198
[TBL] [Abstract][Full Text] [Related]
4. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.
Javorsky M; Klimcakova L; Schroner Z; Zidzik J; Babjakova E; Fabianova M; Kozarova M; Tkacova R; Salagovic J; Tkac I
Eur J Intern Med; 2012 Apr; 23(3):245-9. PubMed ID: 22385882
[TBL] [Abstract][Full Text] [Related]
5. Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.
Mannino GC; Sesti G
Mol Diagn Ther; 2012 Oct; 16(5):285-302. PubMed ID: 23018631
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.
Glamočlija U; Jevrić-Čaušević A
Acta Pharm; 2010 Dec; 60(4):387-406. PubMed ID: 21169132
[TBL] [Abstract][Full Text] [Related]
7. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
Sesti G; Laratta E; Cardellini M; Andreozzi F; Del Guerra S; Irace C; Gnasso A; Grupillo M; Lauro R; Hribal ML; Perticone F; Marchetti P
J Clin Endocrinol Metab; 2006 Jun; 91(6):2334-9. PubMed ID: 16595597
[TBL] [Abstract][Full Text] [Related]
8. The role of adiponectin gene variants in glycemic control in patients with Type 2 diabetes.
Al-Azzam SI; Khabour OF; Alzoubi KH; Mukattash TL; Ghanma M; Saleh H
Endocr Res; 2014; 39(1):13-7. PubMed ID: 23772547
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
Erem C; Ozbas HM; Nuhoglu I; Deger O; Civan N; Ersoz HO
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):295-302. PubMed ID: 24710641
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Pathogenesis, Therapeutic Targets/Drug Action and Pharmacogenetics of Type 2 Diabetes: Is there a Future for Personalised Medicine?
Engwa GA; Nweke FN; Karngong GN; Afiukwa CA; Nwagu KE
Endocr Metab Immune Disord Drug Targets; 2020; 20(10):1569-1589. PubMed ID: 32334506
[TBL] [Abstract][Full Text] [Related]
11. Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus.
Mitchell BD; Eby EL; Lage MJ
Curr Med Res Opin; 2013 Dec; 29(12):1587-97. PubMed ID: 23886028
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes.
Engelbrechtsen L; Andersson E; Roepstorff S; Hansen T; Vestergaard H
Pharmacogenet Genomics; 2015 Oct; 25(10):475-84. PubMed ID: 26181639
[TBL] [Abstract][Full Text] [Related]
13. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions.
Holstein A; Beil W
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):225-41. PubMed ID: 19331589
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
15. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of Antidiabetic Drugs.
Srinivasan S; Yee SW; Giacomini KM
Adv Pharmacol; 2018; 83():361-389. PubMed ID: 29801583
[TBL] [Abstract][Full Text] [Related]
17. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
18. Pathways targeted by antidiabetes drugs are enriched for multiple genes associated with type 2 diabetes risk.
Segrè AV; Wei N; ; ; Altshuler D; Florez JC
Diabetes; 2015 Apr; 64(4):1470-83. PubMed ID: 25368101
[TBL] [Abstract][Full Text] [Related]
19. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
[TBL] [Abstract][Full Text] [Related]
20. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
